ECOSCIENCE CORPORATION – Trademark Portfolio

Entity Type: 03

ECOSCIENCE CORPORATION holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 12 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include BIO-SAVE. The owner is based in Amherst, MA.

85 North Whitney Street

Amherst, MA 01002

13 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

ECOSCIENCE CORPORATION's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (12 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does ECOSCIENCE CORPORATION have?

ECOSCIENCE CORPORATION has 13 U.S. trademarks filed with the USPTO. Of these, 1 registered, 6 abandoned, 6 cancelled.

What trademark classes does ECOSCIENCE CORPORATION file in?

ECOSCIENCE CORPORATION files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are ECOSCIENCE CORPORATION's most well-known trademarks?

ECOSCIENCE CORPORATION's registered trademark portfolio includes well-known marks such as BIO-SAVE. These are among 1 currently registered trademark in the portfolio.

What is ECOSCIENCE CORPORATION's trademark registration success rate?

ECOSCIENCE CORPORATION has a 8% trademark registration rate, with 1 out of 13 resolved applications resulting in successful registration. Currently, 0 applications are pending review.